Jay Donovan Wu - 18 Mar 2026 Form 3 Insider Report for Ascendis Pharma A/S (ASND)

Role
EVP & President US Market
Signature
/s/ Michael Wolff Jensen as attorney-in-fact for Jay Wu
Issuer symbol
ASND
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 18:06:23 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wu Jay Donovan EVP & President US Market C/O ASCENDIS PHARMA A/S, TUBORG BOULEVARD 12, HELLERUP, DENMARK /s/ Michael Wolff Jensen as attorney-in-fact for Jay Wu 18 Mar 2026 0002079744

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ASND Ordinary Shares 1,068 18 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ASND Warrants 18 Mar 2026 Ordinary Shares 45,078 $131.57 Direct F2
holding ASND Restricted Stock Units 18 Mar 2026 Ordinary Shares 3,333 Direct F3, F4
holding ASND Restricted Stock Units 18 Mar 2026 Ordinary Shares 9,553 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.
F2 The warrants vested 25% on January 14, 2026 and thereafter in 36 equal monthly installments.
F3 The restricted stock units vest in two equal annual installments beginning on March 1, 2027.
F4 Each restricted stock unit represents a contingent right to receive one ADS.
F5 The restricted stock units vest in three equal annual installments beginning on March 1, 2027.